JP5432705B2 - 凍結乾燥された治療用ペプチボディ製剤 - Google Patents

凍結乾燥された治療用ペプチボディ製剤 Download PDF

Info

Publication number
JP5432705B2
JP5432705B2 JP2009506615A JP2009506615A JP5432705B2 JP 5432705 B2 JP5432705 B2 JP 5432705B2 JP 2009506615 A JP2009506615 A JP 2009506615A JP 2009506615 A JP2009506615 A JP 2009506615A JP 5432705 B2 JP5432705 B2 JP 5432705B2
Authority
JP
Japan
Prior art keywords
protein
peptide
formulation
sucrose
lyophilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009506615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009534392A (ja
Inventor
カラハン，ウイリアム・ジエイ
レメル，リチヤード・エル，ジユニア
ラトナスワーミ，ガヤトリー
ラピポブ，ラミル・エフ
リウ，デインジヤン
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38625630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5432705(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2009534392A publication Critical patent/JP2009534392A/ja
Application granted granted Critical
Publication of JP5432705B2 publication Critical patent/JP5432705B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
JP2009506615A 2006-04-21 2007-04-20 凍結乾燥された治療用ペプチボディ製剤 Active JP5432705B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79399706P 2006-04-21 2006-04-21
US60/793,997 2006-04-21
US11/788,697 US9283260B2 (en) 2006-04-21 2007-04-19 Lyophilized therapeutic peptibody formulations
US11/788,697 2007-04-19
PCT/US2007/009712 WO2007124090A2 (en) 2006-04-21 2007-04-20 Lyophilized therapeutic peptibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013201931A Division JP5873854B2 (ja) 2006-04-21 2013-09-27 凍結乾燥された治療用ペプチボディ製剤

Publications (2)

Publication Number Publication Date
JP2009534392A JP2009534392A (ja) 2009-09-24
JP5432705B2 true JP5432705B2 (ja) 2014-03-05

Family

ID=38625630

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2009506615A Active JP5432705B2 (ja) 2006-04-21 2007-04-20 凍結乾燥された治療用ペプチボディ製剤
JP2013201931A Active JP5873854B2 (ja) 2006-04-21 2013-09-27 凍結乾燥された治療用ペプチボディ製剤
JP2015208065A Active JP6356106B2 (ja) 2006-04-21 2015-10-22 凍結乾燥された治療用ペプチボディ製剤
JP2018111720A Active JP6787953B2 (ja) 2006-04-21 2018-06-12 凍結乾燥された治療用ペプチボディ製剤
JP2020128961A Pending JP2021006525A (ja) 2006-04-21 2020-07-30 凍結乾燥された治療用ペプチボディ製剤
JP2022130437A Pending JP2022166219A (ja) 2006-04-21 2022-08-18 凍結乾燥された治療用ペプチボディ製剤

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2013201931A Active JP5873854B2 (ja) 2006-04-21 2013-09-27 凍結乾燥された治療用ペプチボディ製剤
JP2015208065A Active JP6356106B2 (ja) 2006-04-21 2015-10-22 凍結乾燥された治療用ペプチボディ製剤
JP2018111720A Active JP6787953B2 (ja) 2006-04-21 2018-06-12 凍結乾燥された治療用ペプチボディ製剤
JP2020128961A Pending JP2021006525A (ja) 2006-04-21 2020-07-30 凍結乾燥された治療用ペプチボディ製剤
JP2022130437A Pending JP2022166219A (ja) 2006-04-21 2022-08-18 凍結乾燥された治療用ペプチボディ製剤

Country Status (38)

Country Link
US (2) US9283260B2 (cg-RX-API-DMAC7.html)
EP (6) EP2018183B1 (cg-RX-API-DMAC7.html)
JP (6) JP5432705B2 (cg-RX-API-DMAC7.html)
KR (2) KR101236042B1 (cg-RX-API-DMAC7.html)
CN (2) CN101484185A (cg-RX-API-DMAC7.html)
AR (1) AR060617A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007240656A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0710508B8 (cg-RX-API-DMAC7.html)
CA (1) CA2649292C (cg-RX-API-DMAC7.html)
CR (3) CR20170130A (cg-RX-API-DMAC7.html)
CY (1) CY1118038T1 (cg-RX-API-DMAC7.html)
DK (1) DK2018183T3 (cg-RX-API-DMAC7.html)
EA (2) EA017085B1 (cg-RX-API-DMAC7.html)
ES (1) ES2599318T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20156253B (cg-RX-API-DMAC7.html)
HR (1) HRP20161653T1 (cg-RX-API-DMAC7.html)
HU (1) HUE032144T2 (cg-RX-API-DMAC7.html)
IL (3) IL194653A (cg-RX-API-DMAC7.html)
JO (1) JO3324B1 (cg-RX-API-DMAC7.html)
LT (1) LT2018183T (cg-RX-API-DMAC7.html)
MA (1) MA30474B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008013393A (cg-RX-API-DMAC7.html)
MY (1) MY162816A (cg-RX-API-DMAC7.html)
NO (1) NO344947B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ596367A (cg-RX-API-DMAC7.html)
PE (1) PE20081196A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014502880A1 (cg-RX-API-DMAC7.html)
PL (1) PL2018183T3 (cg-RX-API-DMAC7.html)
PT (1) PT2018183T (cg-RX-API-DMAC7.html)
RS (1) RS55428B1 (cg-RX-API-DMAC7.html)
SG (2) SG182887A1 (cg-RX-API-DMAC7.html)
SI (1) SI2018183T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN08391A1 (cg-RX-API-DMAC7.html)
TW (1) TWI352598B (cg-RX-API-DMAC7.html)
UA (2) UA116080C2 (cg-RX-API-DMAC7.html)
UY (1) UY30302A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007124090A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200808485B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014040441A (ja) * 2006-04-21 2014-03-06 Amgen 凍結乾燥された治療用ペプチボディ製剤

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1124961B9 (en) 1998-10-23 2010-07-21 Kirin-Amgen Inc. Thrombopoietic compounds
ATE365052T1 (de) 1999-02-22 2007-07-15 Univ Connecticut Neue albuminfreie faktor viii formulierungen
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
CZ300710B6 (cs) 1999-06-01 2009-07-22 Biogen Idec Ma Inc. Použití blokující monoklonální protilátky proti VLA-1 pro výrobu farmaceutického prípravku k lécení zánetlivých onemocnení
KR100927670B1 (ko) 2001-04-13 2009-11-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｖｌａ-1에 대한 항체들
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2638823A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
AU2011265555B2 (en) * 2006-04-21 2016-03-10 Amgen Inc. Lyophilized therapeutic peptibody formulations
CN105381459A (zh) 2006-05-25 2016-03-09 比奥根Ma公司 治疗中风的方法
TW200950799A (en) 2008-05-07 2009-12-16 Merrion Res Iii Ltd Compositions of GnRH related compounds and processes of preparation
KR101752508B1 (ko) 2008-11-07 2017-06-29 백스터 인터내셔널 인코포레이티드 제8 인자 제형
US20120183546A1 (en) 2009-09-23 2012-07-19 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
JP5638628B2 (ja) * 2010-01-19 2014-12-10 ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅｃｏ．，Ｌｔｄ． 持続型エリスロポエチン結合体の液剤
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
CN103269716B (zh) 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
CA2819246C (en) 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Liquid viral formulations
JP5759211B2 (ja) * 2011-03-11 2015-08-05 三洋化成工業株式会社 凍結乾燥方法
WO2013003606A1 (en) 2011-06-29 2013-01-03 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
DE102011055889B4 (de) * 2011-11-30 2013-08-01 Otc Gmbh Verfahren zur Herstellung eines Protein-Hydrolysates
CN102586217A (zh) * 2011-12-16 2012-07-18 深圳市海普瑞药业股份有限公司 肝素黄杆菌肝素酶ⅰ、ⅱ、ⅲ的冻干保存方法
RU2482128C1 (ru) * 2011-12-28 2013-05-20 Замертон Холдингс Лимитед Пептиды, обладающие цитопротекторной активностью
MX370199B (es) 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
EP2644186A1 (en) 2012-03-26 2013-10-02 OTC GmbH Hair conditioning composition for permanent and semi-permanent hair coloration applications
RU2014151424A (ru) * 2012-06-25 2016-08-20 Эмерджент Продакт Девелопмент Гейзерсбург Инк. Термостабильные составы вакцины
MX2015000863A (es) 2012-07-19 2016-05-05 Alethia Biotherapeutics Inc Anticuerpos anti-siglec-15.
EP2698162A1 (en) * 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
CA2906835A1 (en) * 2013-03-15 2014-09-18 Amgen Inc. Myostatin antagonism in human subjects
CN104274827B (zh) * 2013-07-01 2020-07-14 上海贺普药业股份有限公司 贺普拉肽的制剂
TW201601741A (zh) * 2013-09-09 2016-01-16 品特生物療法有限公司 用於治療ｅｓｒｄ病患之ｐｅｗ的肌肉生長抑制素拮抗劑
PL3065756T3 (pl) * 2013-11-07 2019-07-31 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Stabilnie przechowywane liofilizowane formulacje tripeptydowe
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2932798C (en) * 2013-12-06 2022-09-20 The Broad Institute, Inc. Formulations for neoplasia vaccines
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
WO2015100344A1 (en) 2013-12-27 2015-07-02 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
WO2015150968A2 (en) 2014-03-29 2015-10-08 Intas Pharmaceuticals Ltd. Lyophilized pharmaceutical composition of fc-peptide fusion protein
LT3149048T (lt) 2014-05-28 2020-05-11 Nono Inc. Tat-nr2b9c chlorido druska
CA2952231A1 (en) * 2014-06-13 2015-12-17 Santa Maria Biotherapeutics, Inc. Formulated receptor polypeptides and related methods
KR20250150675A (ko) * 2014-08-20 2025-10-20 포톨라 파마슈티컬스, 인코포레이티드 인자 xa 해독제용 동결건조된 제형
JP6671141B2 (ja) * 2014-10-21 2020-03-25 大日本住友製薬株式会社 懸濁液剤
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
US10857229B2 (en) 2015-04-30 2020-12-08 Amgen Inc. Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane
KR20180010229A (ko) 2015-05-20 2018-01-30 더 브로드 인스티튜트, 인코퍼레이티드 공유 신생항원
ES3013312T3 (en) 2015-12-17 2025-04-11 Univ Johns Hopkins Ameliorating systemic sclerosis with death receptor agonists
JP6968802B2 (ja) 2016-01-08 2021-11-17 アセンディス ファーマ グロース ディスオーダーズ エー／エス 環部分にキャリア結合を有するｃｎｐプロドラッグ
IL318754A (en) 2016-01-08 2025-04-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
MY195190A (en) 2016-01-08 2023-01-11 Ascendis Pharma Growth Disorders As Controlled-Release Cnp Agonists With Increased Nep Stability
JP6992262B2 (ja) * 2016-03-31 2022-02-15 東ソー株式会社 変性抗体測定試薬の製造方法
US11084879B2 (en) 2016-04-07 2021-08-10 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
WO2017197199A1 (en) * 2016-05-13 2017-11-16 Askgene Pharma Inc. Novel angiopoietin 2, vegf dual antagonists
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP2017155046A (ja) * 2017-04-05 2017-09-07 イーストポンド・ラボラトリーズ・リミテッド シクロデキストリンを含有する細胞水和組成物
MA50239A (fr) 2017-09-15 2020-07-22 Amgen Inc Procédé de formulation pharmaceutique lyophilisée d'une protéine thérapeutique
US20200255496A1 (en) * 2017-09-18 2020-08-13 Amgen Inc. Vegfr-fc fusion protein formulations
KR20250002808A (ko) * 2017-12-22 2025-01-07 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
CN108159413B (zh) * 2018-01-10 2021-07-06 杭州洪桥中科基因技术有限公司 一种动物用冻干活疫苗及其制备方法
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
CA3099049A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
CA3105751A1 (en) * 2018-07-31 2020-02-06 Amgen Inc. Pharmaceutical formulations of masked antibodies
KR102893903B1 (ko) 2019-02-11 2025-12-01 아센디스 파마 그로우쓰 디스오더스 에이/에스 Cnp 접합체의 건조 약학 제제
JOP20210229A1 (ar) 2019-02-18 2023-01-30 Lilly Co Eli صيغة جسم مضاد علاجي
CN113660953A (zh) * 2019-04-01 2021-11-16 豪夫迈·罗氏有限公司 用于稳定含蛋白质制剂的组合物和方法
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
EP3744319B1 (en) 2019-05-28 2022-10-19 Ilkogen Ilac Sanayi Ve Ticaret A.S. A stable lyophilized formulation for hybrid fc fused g-csf
JP2019178154A (ja) * 2019-06-18 2019-10-17 イーストポンド・ラボラトリーズ・リミテッド シクロデキストリンを含有する細胞水和組成物
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
JP2023529764A (ja) * 2019-12-02 2023-07-12 アルタバント・サイエンシズ・ゲーエムベーハー 下気道障害の処置
CN115348967A (zh) * 2019-12-03 2022-11-15 洪明奇 寡胜肽，其检测套组，其医药组合物与医药组合物的用途
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
CN120904344A (zh) * 2021-03-31 2025-11-07 杭州嘉因生物科技有限公司 靶向vegf和血管生成素的融合分子及其用途
CN118317787A (zh) 2021-12-01 2024-07-09 Ucb生物制药有限责任公司 包含Fab-PEG的制剂
US20240076597A1 (en) * 2022-09-02 2024-03-07 Terumo Bct, Inc. Methods for cell expansion, differentiation, and/or harvesting of natural killer cells using hollow-fiber membranes
WO2024133908A1 (en) * 2022-12-23 2024-06-27 Syna Therapeutics, S.L. Stable pharmaceutical compositions comprising romiplostim
WO2024263570A1 (en) * 2023-06-23 2024-12-26 The Regents Of The University Of Michigan Nanoparticle compositions associated with peptides
CN118126120B (zh) * 2023-09-14 2024-12-06 海南大学 抑制Aβ42聚集并降低其细胞毒作用的三肽化合物

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
DE3244265A1 (de) 1982-11-30 1984-05-30 Cassella Ag, 6000 Frankfurt Weichmacheremulsion, verfahren zu ihrer herstellung und ihre anwendung
US4503235A (en) 1983-03-11 1985-03-05 Warner-Lambert Company Process for producing 4-carbamoyl-1H-imidazolium-5-olate
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0315456B1 (en) 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
SG89295A1 (en) 1991-03-15 2002-06-18 Amgen Inc Pegylation of polypeptides
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
AU666388B2 (en) 1992-05-26 1996-02-08 Immunex Corporation Novel cytokine that binds CD30
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
GB9225448D0 (en) 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5880096A (en) 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5608035A (en) 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5786331A (en) 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5844929A (en) * 1994-02-24 1998-12-01 British Telecommunications Public Limited Company Optical device with composite passive and tapered active waveguide regions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU693478B2 (en) 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity
IL116026A (en) 1994-11-22 2005-08-31 Rhone Poulenc Rorer Sa Peptides capable of linking to the sh3 domain of gap, nucleotide sequences encoding the same, their preparation and uses
US5888763A (en) 1994-12-30 1999-03-30 The Rockefeller University Peptides specific for the first Crk-SH3 domain
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
IL113159A0 (en) 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
PT2275119E (pt) * 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
US5746516A (en) 1995-08-11 1998-05-05 Hitachi Powdered Metals Co., Ltd. Porous bearing system having internal grooves and electric motor provided with the same
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
JPH09151200A (ja) 1995-09-29 1997-06-10 Ajinomoto Co Inc ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US5714577A (en) 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
IL117223A0 (en) 1996-02-22 1996-06-18 Yeda Res & Dev Antipathogenic polypeptides and compositions comprising them
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
AU2597897A (en) 1996-03-28 1997-10-17 Brigham And Women's Hospital Peptide ligands of the urokinase receptor
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
FR2748028B1 (fr) 1996-04-30 1998-08-14 Lab Francais Du Fractionnement Peptides derives du facteur von willebrand et leur utilisation comme anticoagulant
WO1997046668A1 (en) 1996-06-07 1997-12-11 Takeda Chemical Industries, Ltd. Novel peptide, process for the production of the same, and use of the same
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
JP2001501600A (ja) 1996-09-10 2001-02-06 ザ バーナム インスティテュート 腫瘍ホーミング分子、それに由来する結合体、およびその使用方法
AU4344697A (en) 1996-10-04 1998-04-24 Amgen, Inc. Pharmaceutical compositions containing an mpl ligand
DE69718341T2 (de) 1996-10-08 2003-10-30 U-Bisys B.V., Utrecht Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
WO1998033812A1 (en) 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
NZ500253A (en) 1997-04-16 2002-09-27 Amgen Inc Osteoprotegerin binding proteins and receptors
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE235513T1 (de) 1997-11-07 2003-04-15 Conjuchem Inc Opioid-konjugate mit endogenen trägerproteinen
WO1999038526A1 (en) 1998-01-29 1999-08-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variant peptide ligands that selectively induce apoptosis
WO1999045026A1 (en) 1998-03-05 1999-09-10 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6235872B1 (en) 1998-03-12 2001-05-22 The Burnham Institute Proapoptotic peptides dependence polypeptides and methods of use
WO1999047151A1 (en) 1998-03-20 1999-09-23 Chugai Pharmaceutical Co., Ltd. Peptide ligands for the erythropoietin receptor
EP0947524A1 (en) 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
CA2327811A1 (en) 1998-04-06 1999-10-14 Advanced Immunit, Inc. Short peptides for treatment of neurological degenerative diseases
DK1075282T3 (da) 1998-04-28 2005-10-10 Applied Research Systems PEG-LHRH-analog-konjugater
EP0972780A1 (en) 1998-05-18 2000-01-19 Applied Research Systems ARS Holding N.V. Il-6 antagonist peptides
BR9910639A (pt) 1998-05-22 2002-01-15 Abbott Lab Drogas anti-angiogênicas compreendendo peptìdeo
US5932548A (en) 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
WO2000001402A1 (en) 1998-07-02 2000-01-13 Envision Biomedical Consulting Antiproliferative and antiviral proteins and peptides
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
WO2000011028A2 (en) 1998-08-21 2000-03-02 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides derived from il-2 and analogues thereof
CZ300762B6 (cs) 1998-10-16 2009-08-05 Biogen Idec Ma Inc. Fúzní proteiny interferonu-beta-1a a jejich použití
EP1124961B9 (en) 1998-10-23 2010-07-21 Kirin-Amgen Inc. Thrombopoietic compounds
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000047740A2 (en) 1999-02-12 2000-08-17 Amgen Inc. Tnf-related proteins
US6635646B1 (en) 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
WO2001083525A2 (en) 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
US6853809B2 (en) 2001-01-30 2005-02-08 Koninklijke Philips Electronics N.V. Camera system for providing instant switching between wide angle and full resolution views of a subject
EP1921088B1 (en) 2001-05-11 2014-10-08 Amgen Inc. Peptides and related molecules that bind to tall-1
RU2180233C1 (ru) 2001-06-26 2002-03-10 Общество с ограниченной ответственностью "Протеиновый контур" Способ получения жидких лекарственных форм рекомбинантных белков
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US20040247588A1 (en) 2002-08-28 2004-12-09 Johnson Robert E. Formulations of modified antibodies and methods of making the same
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
EA009056B1 (ru) 2002-12-20 2007-10-26 Амген, Инк. Связывающие агенты, ингибирующие миостатин
WO2006010057A2 (en) 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
CA2580796C (en) 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EP3035305B1 (en) 2014-12-18 2016-11-16 Axis AB Enclosure and arrangement for recess mounting of a camera or camera head

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014040441A (ja) * 2006-04-21 2014-03-06 Amgen 凍結乾燥された治療用ペプチボディ製剤

Also Published As

Publication number Publication date
SG182887A1 (en) 2012-08-30
PE20081196A1 (es) 2008-09-04
WO2007124090A3 (en) 2008-12-11
EP2018183B1 (en) 2016-09-07
DK2018183T3 (en) 2016-11-28
BRPI0710508A2 (pt) 2012-10-30
EP2594285A1 (en) 2013-05-22
HUE032144T2 (en) 2017-08-28
JP2016065060A (ja) 2016-04-28
RS55428B1 (sr) 2017-04-28
MA30474B1 (fr) 2009-06-01
AR060617A1 (es) 2008-07-02
JP6787953B2 (ja) 2020-11-18
PL2018183T3 (pl) 2017-04-28
EA017085B1 (ru) 2012-09-28
US20090258017A1 (en) 2009-10-15
UY30302A1 (es) 2007-10-31
JP5873854B2 (ja) 2016-03-01
MY162816A (en) 2017-07-31
CR20170130A (es) 2017-06-15
US10166189B2 (en) 2019-01-01
SI2018183T1 (sl) 2017-01-31
JP2014040441A (ja) 2014-03-06
HRP20161653T1 (hr) 2017-01-13
ES2599318T3 (es) 2017-02-01
EA201270625A1 (ru) 2012-12-28
LT2018183T (lt) 2016-11-25
EA200802170A1 (ru) 2009-06-30
BRPI0710508B1 (pt) 2018-10-23
US20160143852A1 (en) 2016-05-26
TW200744624A (en) 2007-12-16
US9283260B2 (en) 2016-03-15
IL194653A0 (en) 2011-08-01
JP2022166219A (ja) 2022-11-01
JP2018150380A (ja) 2018-09-27
JP2009534392A (ja) 2009-09-24
NZ596367A (en) 2013-09-27
TWI352598B (en) 2011-11-21
KR20090005204A (ko) 2009-01-12
NO20084893L (no) 2009-01-20
CN107789325A (zh) 2018-03-13
EP2594286A1 (en) 2013-05-22
IL248156B (en) 2018-07-31
SG10201501296SA (en) 2015-04-29
WO2007124090A2 (en) 2007-11-01
EP2594284A1 (en) 2013-05-22
CN101484185A (zh) 2009-07-15
IL224966A (en) 2017-10-31
MX2008013393A (es) 2009-03-06
EA022424B1 (ru) 2015-12-30
EP2594285B1 (en) 2016-08-10
CR10442A (es) 2009-02-19
GEP20156253B (en) 2015-03-10
JP6356106B2 (ja) 2018-07-11
JO3324B1 (ar) 2019-03-13
UA116080C2 (uk) 2018-02-12
TNSN08391A1 (en) 2010-04-14
KR20120114384A (ko) 2012-10-16
PT2018183T (pt) 2016-12-02
UA99815C2 (ru) 2012-10-10
CA2649292C (en) 2017-01-17
KR101227278B1 (ko) 2013-01-28
PH12014502880A1 (en) 2016-01-18
BRPI0710508B8 (pt) 2021-05-25
AU2007240656A1 (en) 2007-11-01
CA2649292A1 (en) 2007-11-01
CR20140274A (es) 2014-07-18
ZA200808485B (en) 2009-08-26
IL194653A (en) 2016-10-31
EP2018183A2 (en) 2009-01-28
JP2021006525A (ja) 2021-01-21
EP2594288A1 (en) 2013-05-22
NO344947B1 (no) 2020-07-27
CY1118038T1 (el) 2017-05-17
KR101236042B1 (ko) 2013-02-21
EP2594287A1 (en) 2013-05-22

Similar Documents

Publication Publication Date Title
JP6356106B2 (ja) 凍結乾燥された治療用ペプチボディ製剤
JP2012149069A (ja) 治療用ペプチド
US9012605B2 (en) Crystalline polypeptides
AU2011265555B2 (en) Lyophilized therapeutic peptibody formulations
HK1128873B (en) Lyophilized therapeutic peptibody formulations

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120807

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121101

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130207

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130307

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130930

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131022

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131206

R150 Certificate of patent or registration of utility model

Ref document number: 5432705

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250